162 related articles for article (PubMed ID: 33513422)
1. Expression, localization and metabolic function of "resurrected" human urate oxidase in human hepatocytes.
Duan Y; Jiang N; Chen J; Chen J
Int J Biol Macromol; 2021 Apr; 175():30-39. PubMed ID: 33513422
[TBL] [Abstract][Full Text] [Related]
2. Functional expression and peroxisomal targeting of rat urate oxidase in monkey kidney cells.
Yeldandi AV; Chu R; Reddy SK; Pan J; Usuda N; Lin Y; Rao MS; Reddy JK
Gene Expr; 1995; 5(2):125-32. PubMed ID: 8821625
[TBL] [Abstract][Full Text] [Related]
3. Coevolution of URAT1 and Uricase during Primate Evolution: Implications for Serum Urate Homeostasis and Gout.
Tan PK; Farrar JE; Gaucher EA; Miner JN
Mol Biol Evol; 2016 Sep; 33(9):2193-200. PubMed ID: 27352852
[TBL] [Abstract][Full Text] [Related]
4. Patients with gout differ from healthy subjects in renal response to changes in serum uric acid.
Liu S; Perez-Ruiz F; Miner JN
Joint Bone Spine; 2017 Mar; 84(2):183-188. PubMed ID: 27324603
[TBL] [Abstract][Full Text] [Related]
5. Molecular Elucidation of a Urate Oxidase from
Chiu YC; Hsu TS; Huang CY; Hsu CH
Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34070642
[TBL] [Abstract][Full Text] [Related]
6. [Rasburicase (Fasturtec)].
Vogt B; Gugger M; Frey FJ
Ther Umsch; 2004 Sep; 61(9):579-82. PubMed ID: 15493120
[TBL] [Abstract][Full Text] [Related]
7. Arxula adeninivorans recombinant urate oxidase and its application in the production of food with low uric acid content.
Trautwein-Schult A; Jankowska D; Cordes A; Hoferichter P; Klein C; Matros A; Mock HP; Baronian K; Bode R; Kunze G
J Mol Microbiol Biotechnol; 2013; 23(6):418-30. PubMed ID: 24022585
[TBL] [Abstract][Full Text] [Related]
8. Potency on lowering serum uric acid in gout patients: a pooled analysis of registrative studies comparing febuxostat vs. allopurinol.
Cutolo M; Cimmino MA; Perez-Ruiz F
Eur Rev Med Pharmacol Sci; 2017 Sep; 21(18):4186-4195. PubMed ID: 29028079
[TBL] [Abstract][Full Text] [Related]
9. Management of gout and hyperuricemia: Multidisciplinary consensus in Taiwan.
Yu KH; Chen DY; Chen JH; Chen SY; Chen SM; Cheng TT; Hsieh SC; Hsieh TY; Hsu PF; Kuo CF; Kuo MC; Lam HC; Lee IT; Liang TH; Lin HY; Lin SC; Tsai WP; Tsay GJ; Wei JC; Yang CH; Tsai WC
Int J Rheum Dis; 2018 Apr; 21(4):772-787. PubMed ID: 29363262
[TBL] [Abstract][Full Text] [Related]
10. GLUT9 influences uric acid concentration in patients with Lesch-Nyhan disease.
Torres RJ; Puig JG
Int J Rheum Dis; 2018 Jun; 21(6):1270-1276. PubMed ID: 29879316
[TBL] [Abstract][Full Text] [Related]
11. Knockout of the urate oxidase gene provides a stable mouse model of hyperuricemia associated with metabolic disorders.
Lu J; Hou X; Yuan X; Cui L; Liu Z; Li X; Ma L; Cheng X; Xin Y; Wang C; Zhang K; Wang X; Ren W; Sun R; Jia Z; Tian Z; Mi QS; Li C
Kidney Int; 2018 Jan; 93(1):69-80. PubMed ID: 28729031
[TBL] [Abstract][Full Text] [Related]
12. Rasburicase represents a new tool for hyperuricemia in tumor lysis syndrome and in gout.
Cammalleri L; Malaguarnera M
Int J Med Sci; 2007 Mar; 4(2):83-93. PubMed ID: 17396159
[TBL] [Abstract][Full Text] [Related]
13. Hyperuricemia and urate nephropathy in urate oxidase-deficient mice.
Wu X; Wakamiya M; Vaishnav S; Geske R; Montgomery C; Jones P; Bradley A; Caskey CT
Proc Natl Acad Sci U S A; 1994 Jan; 91(2):742-6. PubMed ID: 8290593
[TBL] [Abstract][Full Text] [Related]
14. Urate oxidase (rasburicase) for treatment of severe acute gout: a case report.
Wipfler-Freibmuth E; Dejaco C; Duftner C; Gaugg M; Kriessmayr-Lungkofler M; Schirmer M
Clin Exp Rheumatol; 2009; 27(4):658-60. PubMed ID: 19772802
[TBL] [Abstract][Full Text] [Related]
15. Serum uric acid-lowering therapies: where are we heading in management of hyperuricemia and the potential role of uricase.
Bomalaski JS; Clark MA
Curr Rheumatol Rep; 2004 Jun; 6(3):240-7. PubMed ID: 15134605
[TBL] [Abstract][Full Text] [Related]
16. Rat urate oxidase produced by recombinant baculovirus expression: formation of peroxisome crystalloid core-like structures.
Alvares K; Widrow RJ; Abu-Jawdeh GM; Schmidt JV; Yeldandi AV; Rao MS; Reddy JK
Proc Natl Acad Sci U S A; 1992 Jun; 89(11):4908-12. PubMed ID: 1594592
[TBL] [Abstract][Full Text] [Related]
17. Safety of urate-lowering therapies: managing the risks to gain the benefits.
Keenan RT
Rheum Dis Clin North Am; 2012 Nov; 38(4):663-80. PubMed ID: 23137576
[TBL] [Abstract][Full Text] [Related]
18. Genetic factors associated with gout and hyperuricemia.
Bleyer AJ; Hart TC
Adv Chronic Kidney Dis; 2006 Apr; 13(2):124-30. PubMed ID: 16580613
[TBL] [Abstract][Full Text] [Related]
19. PEG-uricase in the management of treatment-resistant gout and hyperuricemia.
Sherman MR; Saifer MG; Perez-Ruiz F
Adv Drug Deliv Rev; 2008 Jan; 60(1):59-68. PubMed ID: 17826865
[TBL] [Abstract][Full Text] [Related]
20. Rationalization design, soluble expression and PEG modification of highly active recombinant human-porcine uricase mutant protein.
Tong M; Wang S; Luan J; Xie Q; Wang L; Shen X; Xiong S
Int J Biol Macromol; 2024 Jun; 269(Pt 1):131989. PubMed ID: 38697425
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
